Executive Director, Analytical Development & Quality Control

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished and visionary Executive Director, Analytical Development Quality Control (ADQC) to provide enterprise leadership for analytical development, quality control, and CMC analytical strategy across our expanding oncology portfolio. As a member of the Pharmaceutical Development Manufacturing (PDM) Extended Leadership Team and the ADQC Leadership Team, this executive will define the long-term analytical vision, build organizational capabilities, and establish scalable analytical and quality control strategies that enable rapid development while supporting late-stage development and commercialization.

Responsibilities

: Technical, Strategic and Organization Partnerships Serve as a key member of the Pharmaceutical Development Manufacturing (PDM) Extended Leadership Team, influencing enterprise CMC strategy, portfolio prioritization, and cross-functional business decisions. Define and execute the enterprise analytical development and quality control strategy aligned with corporate objectives, portfolio priorities, and commercialization goals. Provide scientific and strategic leadership for analytical development across the product lifecycle, including analytical characterization, specification development, impurity profiling, stability, comparability, and analytical method lifecycle management.

Establish phase-appropriate analytical control strategies that ensure product quality, process understanding, regulatory compliance, and successful technology transfer from early development through commercialization. Partner cross-functionally to ensure analytical strategies support accelerated development while maintaining scientific rigor, regulatory compliance, and commercial readiness. Provide executive analytical leadership for global regulatory submissions, including INDs, IMPDs, NDAs, MAAs, JNDAs, and other international filings, and represent the company during health authority interactions, inspections, and regulatory meetings.

Champion innovation through implementation of advanced analytical technologies, laboratory digitalization, automation, and data-driven approaches. Build organizational capability by fostering scientific excellence, innovation, continuous improvement, accountability, collaboration, and inclusion across the ADQC organization. Foster strategic scientific collaborations with external experts, industry consortia, and technology partners while leveraging emerging analytical technologies and best practices.

External Partnerships Define and execute the enterprise strategy for a high-performing global network of CDMOs, CROs, and contract testing laboratories. Build strategic partnerships that enhance technical capabilities, operational scalability, business continuity, and commercialization readiness. Provide executive oversight of outsourced analytical development, analytical method validation, technology transfer, and lifecycle management across the external network.

Establish governance models, performance metrics, and executive business review processes to ensure operational excellence, quality, regulatory compliance, and continuous improvement.